Healthcare & Pharmaceutical Market Research in the UAE

    BioNixus is a pharmaceutical market research firm in Dubai and the UAE, designing and executing primary studies for healthcare and pharma teams launching products across DHA, DoH, and MOHAP-regulated channels. Our healthcare market research agency covers HCP insight, KOL mapping, patient journey studies, and payer access research — purpose-built for the UAE's multi-emirate health system.

    Looking for all-industry market research? Market research company in the UAE covers FMCG, retail, BFSI, telecom, real estate, and technology.

    Best healthcare market research company in UAE

    BioNixus is a leading healthcare market research company in the UAE, specialising in HCP surveys, KOL mapping, and market access research compliant with MOHAP, DHA, and DOH Abu Dhabi requirements.

    • HCP and Physician SurveysBilingual (English/Arabic) interviews and surveys across physicians, pharmacists, and nurses in Dubai, Abu Dhabi, and Sharjah.
    • KOL Mapping and Influence AnalysisIdentify key opinion leaders and map influence networks by therapy area across UAE health systems.
    • Market Access and Pricing ResearchFormulary committee research, DHA and DOH tender analysis, and willingness-to-pay studies across UAE healthcare channels.

    BioNixus delivers primary healthcare market research in the UAE with MOHAP, DHA, and DOH-aligned methodologies across public and private health systems.

    What we research: therapeutic areas and segments in the UAE

    Oncology & hematology

    Dubai Oncology Centre, AUH, and KOL mapping across DHA and DoH specialist networks

    Biologics & biosimilars

    Biologic market access, biosimilar substitution attitudes, and formulary positioning in UAE private hospitals

    Precision medicine

    Genomics adoption, personalized therapy readiness, and biomarker testing behaviour across UAE oncology centers

    Pharmacovigilance

    Post-marketing surveillance design and MOHAP pharmacovigilance framework research

    Diabetes & metabolic

    Type 1 and Type 2 treatment algorithms, GLP-1 adoption, and payer coverage across DHA and DoH channels

    Rare disease & orphan products

    UAE patient community mapping, specialist access, and compassionate use program research

    Medical devices & diagnostics

    Device adoption, procurement committee behavior, and health technology assessment research for UAE hospital tenders

    Vaccines & infectious disease

    MOHAP vaccine programme awareness, uptake drivers, and hesitancy research across UAE population segments

    Generic injectables & specialty pharma

    Generic substitution attitudes, injectable tender dynamics, and hospital formulary management across UAE hospital groups

    Research audiences: who we reach in the UAE

    HCPs — physicians and specialists

    Prescribing oncologists, diabetologists, cardiologists, and primary care physicians across Dubai, Abu Dhabi, Sharjah, and Northern Emirates hospitals and clinics.

    KOLs — key opinion leaders

    UAE academic and clinical thought leaders in target therapy areas. BioNixus maps influence networks across DHA, DoH, and MOHAP clinical advisory structures.

    Patients and caregivers

    Patient journey studies, quality-of-life research, and support program needs assessment — conducted with ethics-appropriate consent and multilingual materials.

    Payers and hospital committee members

    Formulary committee chairs, insurance medical directors, hospital procurement leads, and DHA/DoH policy advisors who shape real-world access.

    Pharmacists

    Community and hospital pharmacist attitudes, dispensing behaviour, generic substitution practices, and patient counselling patterns across UAE retail and institutional pharmacy.

    Healthcare research methodology

    Every BioNixus UAE healthcare study begins with a single commercial or access decision — launch sequencing, payer narrative, KOL prioritization, or competitive positioning. Instruments, sample frames, and analysis plans are designed backward from that decision.

    We combine quantitative rigor (structured HCP surveys, segmentation, adoption models) with qualitative depth (in-depth interviews, virtual advisory boards, paired physician-payer modules) so leadership sees both the metric and the reason behind it.

    Fieldwork follows healthcare research standards: screened and verified respondents, documented consent, de-identified reporting, and bilingual materials reviewed for clinical accuracy before launch. Arabic and English execution is standard across all UAE programs.

    For advisory board and real-world evidence (RWE) programs, BioNixus designs sessions compatible with MOHAP, DHA, and DoH regulatory frameworks — ensuring findings can support access dossiers and reimbursement submissions.

    Regulatory and market access depth: DHA, DoH, and MOHAP

    The UAE's multi-emirate health system means pharmaceutical market research must account for three distinct regulatory and procurement realities. Dubai Health Authority (DHA) manages Dubai's public and insurance-linked formulary; Department of Health (DoH) governs Abu Dhabi's health insurance mandate and hospital formularies; MOHAP oversees federal drug registration and post-marketing surveillance. BioNixus designs studies that reflect this emirate-level variation rather than treating the UAE as a single market.

    Private insurance penetration is among the highest in the GCC — mandatory health insurance in Dubai and Abu Dhabi means formulary placement directly determines commercial access. Research programs map both the clinical access pathway (DHA/DoH approval, formulary committee timing) and the commercial execution layer (insurance preferred lists, co-pay dynamics, hospital tender cycles).

    Dubai's health cluster — Dubai Healthcare City (DHCC), Mediclinic City Hospital, Cleveland Clinic Abu Dhabi, and the Aster network — concentrates specialist prescribing. BioNixus KOL maps and HCP studies segment by hospital group, specialty, and emirate so you target influence where it actually sits for your therapy area.

    Why pharmaceutical teams choose BioNixus in the UAE

    • ✓Specialist in pharma and healthcare research — not a generalist panel company running healthcare as a sideline
    • ✓Verified UAE physician and specialist panels across Dubai, Abu Dhabi, and Northern Emirates
    • ✓Bilingual Arabic–English fieldwork with culturally validated instruments
    • ✓Deep DHA, DoH, and MOHAP regulatory context built into study design
    • ✓Dual quantitative and qualitative capability in one team — no subcontracting
    • ✓Real-world evidence and advisory board program design compatible with UAE access submissions
    • ✓15+ years of healthcare research experience across 38 countries
    • ○[TODO: Add specific UAE therapy area case study once client approval received]

    Related UAE healthcare research resources

    Top pharmaceutical companies in UAEUAE pharmaceutical market researchPharmaceutical market research DubaiHealthcare & pharma market research UAE (hub)All-industry market research in the UAEHealthcare market research in Saudi Arabia

    FAQs

    What are the best pharmaceutical market research firms in Dubai?

    BioNixus is a leading pharmaceutical market research firm in Dubai, delivering HCP, KOL, patient, and payer studies for DHA, DoH, and MOHAP-aligned launches. We combine primary research depth with Dubai-specific panel access and bilingual fieldwork.

    What does a healthcare market research agency in Dubai typically do?

    A healthcare market research agency in Dubai designs and executes studies covering physician attitudes, payer access, patient journeys, and competitive landscape for pharmaceutical and medical device companies launching in the UAE.

    How is healthcare market research in Dubai different from Abu Dhabi?

    Dubai operates under DHA (Dubai Health Authority) while Abu Dhabi is governed by DoH (Department of Health). Formulary processes, hospital procurement, and insurance structures differ between the two emirates. BioNixus segments studies by emirate where decision-making differs.

    What therapeutic areas do pharmaceutical market research companies in Dubai cover?

    BioNixus covers oncology, diabetes, cardiology, immunology, rare diseases, biologics, biosimilars, vaccines, medical devices, and diagnostics across the UAE market.

    Can BioNixus recruit HCPs and KOLs in the UAE?

    Yes. We maintain physician and specialist panels across Dubai and Abu Dhabi. For scarce specialties like oncology or rare disease, we extend to hospital networks and medical association directories with longer recruitment planning.

    What is the typical timeline for healthcare market research in the UAE?

    Focused HCP surveys complete in 3–4 weeks. Full mixed-method programs including payer depth and advisory modules typically run 5–8 weeks depending on therapy scarcity and ethics requirements.

    Does healthcare market research in Dubai cover precision medicine and biologics?

    Yes. BioNixus runs studies covering biologics, biosimilars, precision medicine, pharmacovigilance, and specialty injectables — reflecting the UAE's growing advanced therapy market across DHA and DoH channels.

    Where can I find general (non-healthcare) market research in the UAE?

    See our Market Research Company in UAE page for all-industry research spanning FMCG, retail, BFSI, telecom, real estate, and technology.

    Discuss your United Arab Emirates pharmaceutical research strategy

    Our team supports pharmaceutical companies with decision-ready insights across the Americas, Europe, and the Middle East using quantitative and qualitative methodologies.

    Request a proposalEmail us

    US No. +1 888 465 5557Europe No. +44 7727 666682Middle East, Africa and Asia No. +20 120 688 2323

    Request a proposal